<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04879628</url>
  </required_header>
  <id_info>
    <org_study_id>ACT16877</org_study_id>
    <secondary_id>2020-004785-19</secondary_id>
    <secondary_id>U1111-1260-3962</secondary_id>
    <nct_id>NCT04879628</nct_id>
  </id_info>
  <brief_title>Proof-of-concept Study for SAR441344 in Relapsing Multiple Sclerosis</brief_title>
  <official_title>A Phase 2, Double-blind, Randomized, Placebo-controlled Study Assessing Efficacy and Safety of SAR441344, a CD40L-antagonist Monoclonal Antibody, in Participants With Relapsing Multiple Sclerosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary Objective:&#xD;
&#xD;
      To determine the efficacy of SAR441344 as measured by reduction of the number of new active&#xD;
      brain lesions&#xD;
&#xD;
      Secondary Objective:&#xD;
&#xD;
        -  To evaluate efficacy of SAR441344 on disease activity as assessed by other MRI measures&#xD;
&#xD;
        -  To evaluate the safety and tolerability of SAR441344&#xD;
&#xD;
        -  To evaluate pharmacokinetics of SAR441344&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The duration of each participant will be no longer than 116 weeks in both parts of the study,&#xD;
      including 4 weeks of screening, at maximum 88 weeks of treatment and 24 weeks of follow-up.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 7, 2021</start_date>
  <completion_date type="Anticipated">December 2023</completion_date>
  <primary_completion_date type="Anticipated">May 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Part A is a 12-week, double-blind, placebo-controlled part; Part B is an open-label SAR441344 treatment part.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of new Gadolinium (Gd)-enhancing T1-hyperintense (GdE T1) lesions</measure>
    <time_frame>At Week 12</time_frame>
    <description>measured by brain magnetic resonance imaging (MRI)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of new or enlarging T2 lesions</measure>
    <time_frame>At Week 12</time_frame>
    <description>measured by brain magnetic resonance imaging (MRI)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total number of GdE T1 lesions</measure>
    <time_frame>At Week 12</time_frame>
    <description>Total number of GdE T1 lesions at Week 12</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events (AEs) and serious adverse events (SAEs)</measure>
    <time_frame>Until Week 112</time_frame>
    <description>Number of participants with AEs and SAEs</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Antidrug antibodies (ADA)</measure>
    <time_frame>Until Week 112</time_frame>
    <description>Number of participants with ADA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic (PK) parameters: Cmax</measure>
    <time_frame>Until Week 112</time_frame>
    <description>maximum concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameter: tmax</measure>
    <time_frame>Until Week 112</time_frame>
    <description>time to Cmax</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameter: AUC0-tau</measure>
    <time_frame>Until Week 112</time_frame>
    <description>area under the curve over the dosing interval</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameter: t1/2z</measure>
    <time_frame>Until Week 112</time_frame>
    <description>elimination half-life</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Multiple Sclerosis</condition>
  <arm_group>
    <arm_group_label>IV SAR441344</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SAR441344 IV</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IV Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo IV</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SC SAR441344</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SAR441344 SC</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SC Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo SC</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SAR441344 IV</intervention_name>
    <description>Pharmaceutical form: Solution Route of administration: IV infusion</description>
    <arm_group_label>IV SAR441344</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo IV</intervention_name>
    <description>Pharmaceutical form: Solution Route of administration: IV infusion</description>
    <arm_group_label>IV Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SAR441344 SC</intervention_name>
    <description>Pharmaceutical form: Solution Route of administration: SC injection</description>
    <arm_group_label>SC SAR441344</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo SC</intervention_name>
    <description>Pharmaceutical form: Solution Route of administration: SC injection</description>
    <arm_group_label>SC Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MRI contrast-enhancing preparations</intervention_name>
    <description>Pharmaceutical form: Solution Route of administration: IV injection</description>
    <arm_group_label>IV Placebo</arm_group_label>
    <arm_group_label>IV SAR441344</arm_group_label>
    <arm_group_label>SC Placebo</arm_group_label>
    <arm_group_label>SC SAR441344</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
          -  Participant must be 18 to 55 years of age inclusive, at the time of signing the&#xD;
             informed consent.&#xD;
&#xD;
          -  The participant must have been diagnosed with RMS (relapsing-remitting MS and&#xD;
             secondary progressive MS participants with relapses) according to the 2017 revision of&#xD;
             the McDonald diagnostic criteria.&#xD;
&#xD;
          -  The participant must have at least 1 documented relapse within the previous year, or&#xD;
             ≥2 documented relapses within the previous 2 years, or ≥1 active Gd-enhancing brain&#xD;
             lesion on an MRI scan in the past 6 months and prior to screening.&#xD;
&#xD;
          -  Body weight within 45 to 120 kg (inclusive) and body mass index (BMI) within the range&#xD;
             18.0 to 35.0 kg/m2 (inclusive) at Screening.&#xD;
&#xD;
          -  Contraceptive use by men and women should be consistent with local regulations&#xD;
             regarding the methods of contraception for those participating in clinical studies.&#xD;
&#xD;
          -  Capable of giving signed informed consent.&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  The participant has been diagnosed with PPMS according to the 2017 revision of the&#xD;
             McDonald diagnostic criteria or with non-relapsing SPMS.&#xD;
&#xD;
          -  The participant has conditions or situations that would adversely affect participation&#xD;
             in this study.&#xD;
&#xD;
          -  The participant has a history of or currently has concomitant medical or clinical&#xD;
             conditions that would adversely affect participation in this study.&#xD;
&#xD;
          -  History, clinical evidence, suspicion or significant risk for thromboembolic events,&#xD;
             as well as myocardial infarction, stroke and/or antiphosholipid syndrome and any&#xD;
             participants requiring antithrombotic treatment.&#xD;
&#xD;
          -  Allergies to humanized monoclonal antibodies or severe post-treatment hypersensitivity&#xD;
             reactions other than localized injection site reaction, to any biological molecule.&#xD;
&#xD;
          -  The participant has received any of the forbidden medications/treatments within the&#xD;
             specified time frame before any baseline assessment.&#xD;
&#xD;
          -  The participant has taken other investigational drug within 3 months or 5-half-live,&#xD;
             whichever is longer, before the screening visit.&#xD;
&#xD;
          -  The participant has an EDSS score &gt;5.5 at the first screening visit.&#xD;
&#xD;
          -  The participant has had a relapse in the 30 days prior to randomization.&#xD;
&#xD;
          -  Positive human immunodeficiency virus (HIV) serology (anti HIV1 and anti HIV2&#xD;
             antibodies) or a known history of HIV infection, active or in remission.&#xD;
&#xD;
          -  Abnormal laboratory test(s) at Screening.&#xD;
&#xD;
          -  Presence of Hepatitis B surface antigen (HBsAg) or anti-Hepatitis B core antibodies&#xD;
             (anti-HBc Ab) at screening or within 3 months prior to first dose of study&#xD;
             intervention.&#xD;
&#xD;
          -  Positive Hepatitis C antibody test result at screening or within 3 months prior to&#xD;
             starting study intervention.&#xD;
&#xD;
        The above information is not intended to contain all considerations relevant to a patient's&#xD;
        potential participation in a clinical trial.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Sciences &amp; Operations</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Trial Transparency email recommended (Toll free number for US &amp; Canada)</last_name>
    <phone>800-633-1610</phone>
    <phone_ext>option 6</phone_ext>
    <email>Contact-US@sanofi.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Investigational Site Number :8400007</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :8400001</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :8400004</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28204</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :1000002</name>
      <address>
        <city>Pleven</city>
        <zip>5800</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :1000003</name>
      <address>
        <city>Sofia</city>
        <zip>1113</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :1000001</name>
      <address>
        <city>Sofia</city>
        <zip>1407</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :1240001</name>
      <address>
        <city>Gatineau</city>
        <state>Quebec</state>
        <zip>J8Y 1W2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :2030003</name>
      <address>
        <city>Brno</city>
        <zip>65691</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :2030002</name>
      <address>
        <city>Hradec Kralove</city>
        <zip>50005</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :2030001</name>
      <address>
        <city>Jihlava</city>
        <zip>58633</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :2030005</name>
      <address>
        <city>Ostrava - Poruba</city>
        <zip>70852</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :7240003</name>
      <address>
        <city>Pamplona</city>
        <state>Navarra</state>
        <zip>31008</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :8040006</name>
      <address>
        <city>Dnipro</city>
        <zip>49005</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :8040010</name>
      <address>
        <city>Dnipro</city>
        <zip>49069</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :8040008</name>
      <address>
        <city>Ivano-Frankivsk</city>
        <zip>76493</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :8040002</name>
      <address>
        <city>Kharkiv</city>
        <zip>61103</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :8040004</name>
      <address>
        <city>Lviv</city>
        <zip>79013</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :8040003</name>
      <address>
        <city>Odesa</city>
        <zip>65025</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :8040005</name>
      <address>
        <city>Vinnytsia</city>
        <zip>21050</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Bulgaria</country>
    <country>Canada</country>
    <country>Czechia</country>
    <country>Spain</country>
    <country>Ukraine</country>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>May 6, 2021</study_first_submitted>
  <study_first_submitted_qc>May 6, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 10, 2021</study_first_posted>
  <last_update_submitted>September 15, 2021</last_update_submitted>
  <last_update_submitted_qc>September 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Sclerosis</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://www.clinicalstudydatarequest.com/</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

